CD1a-STAb T cells

CD1a-STAb T cells are genetically engineered T cells designed for immunotherapy of cortical T-cell acute lymphoblastic leukemia (coT-ALL), particularly in relapsed or refractory cases. Unlike conventional CAR-T cells, these T cells are modified to secrete bispecific T cell-engaging antibodies (STAb; soluble T cell activators) that simultaneously target CD1a (expressed on malignant T-ALL cells) and CD3 (on T cells), facilitating targeted cytotoxicity. By recruiting both engineered and bystander (unmodified) T cells, this approach enhances anti-tumor activity, even in patients with low numbers of healthy T lymphocytes, and may reduce the risk of cytokine release syndrome, a common complication in CAR-T therapy. CD1a-STAb T cells represent an evolution of CAR-T-based cell therapy, aiming for effective and persistent tumor elimination with potentially improved safety and efficacy[1][2][3][4][5][6][7].

Other names

CD1a x CD3 STAb T cellsCD-1a x CD3 STAb T cellsCD 1a x CD3 STAb T cellsCD1a-secreting T-Engager T cellsCD-1a-secreting T-Engager T cellsCD 1a-secreting T-Engager T cellsCD1a STAb-TCD-1a STAb-TCD 1a STAb-TSTAb-T cells targeting CD1aCD1a T cell-engager secreting T cellsCD-1a T cell-engager secreting T cellsCD 1a T cell-engager secreting T cells